Ionis Pharmaceuticals, Inc. Realized Investment Gains (Losses)
Ionis Pharmaceuticals, Inc. (IONS) reported Realized Investment Gains (Losses) of $12.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for the quarter ending 2026-06-30 was -$10.18M.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for the quarter ending 2026-03-31 was $22.58M.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for the quarter ending 2025-12-31 was -$157.00K.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for the quarter ending 2025-09-30 was $29.91M, a 3294.78% increase year-over-year.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for fiscal 2025 was $9.28M.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for fiscal 2024 was -$2.89M.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for fiscal 2023 was -$1.59M.
- Ionis Pharmaceuticals, Inc. realized investment gains (losses) for fiscal 2022 was -$224.00K, a 120.51% decline from fiscal 2021.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $12.40M 10-Q · filed 2026-07-29 | $12.24M derived: sum of 3 quarters · filed 2026-07-29 | $42.15M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $22.58M 10-Q · filed 2026-04-29 | $22.43M derived: sum of 2 quarters · filed 2026-04-29 | $52.33M derived: sum of 3 quarters · filed 2026-04-29 | $33.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $29.75M derived: sum of 2 quarters · filed 2026-02-26 | $11.13M derived: sum of 3 quarters · filed 2026-07-29 | $9.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $11.29M derived: sum of 2 quarters · filed 2026-07-29 | $9.44M 10-Q · filed 2025-10-29 | $6.87M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$18.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$20.47M 10-Q · filed 2026-07-29 | -$23.04M derived: sum of 3 quarters · filed 2026-07-29 | -$22.16M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$1.85M 10-Q · filed 2026-04-29 | -$4.42M derived: sum of 2 quarters · filed 2026-04-29 | -$3.54M derived: sum of 3 quarters · filed 2026-04-29 | -$7.07M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.69M derived: sum of 2 quarters · filed 2026-02-26 | -$5.22M derived: sum of 3 quarters · filed 2026-02-26 | -$2.89M 10-K · filed 2026-02-26 |
| 2024-09-30 | $881.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$2.65M derived: sum of 2 quarters · filed 2025-10-29 | -$320.00K 10-Q · filed 2025-10-29 | -$480.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$1.20M 10-Q · filed 2025-07-30 | -$1.36M derived: sum of 3 quarters · filed 2026-02-26 | -$3.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.33M 10-Q · filed 2025-04-30 | $2.17M derived: sum of 2 quarters · filed 2026-02-26 | $442.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.89M derived: sum of 2 quarters · filed 2026-02-26 | -$1.06M derived: sum of 3 quarters · filed 2026-02-26 | -$1.59M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$900.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.43M 10-Q · filed 2024-11-06 | -$1.43M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $830.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $301.00K 10-Q · filed 2024-08-01 | $305.00K derived: sum of 3 quarters · filed 2025-02-19 | $131.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$529.00K 10-Q · filed 2024-05-07 | -$525.00K derived: sum of 2 quarters · filed 2025-02-19 | -$699.00K derived: sum of 3 quarters · filed 2025-02-19 | -$763.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$170.00K derived: sum of 2 quarters · filed 2025-02-19 | -$234.00K derived: sum of 3 quarters · filed 2025-02-19 | -$224.00K 10-K · filed 2025-02-19 |
| 2022-09-30 | -$174.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$238.00K derived: sum of 2 quarters · filed 2023-11-02 | -$228.00K 10-Q · filed 2023-11-02 | -$69.00K derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$54.00K 10-Q · filed 2023-08-09 | $105.00K derived: sum of 3 quarters · filed 2024-02-21 | $165.00K derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $10.00K 10-Q · filed 2023-05-03 | $169.00K derived: sum of 2 quarters · filed 2024-02-21 | $229.00K derived: sum of 3 quarters · filed 2024-02-21 | $1.09M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $219.00K derived: sum of 2 quarters · filed 2024-02-21 | $1.08M derived: sum of 3 quarters · filed 2024-02-21 | $1.09M 10-K · filed 2024-02-21 |
| 2021-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $920.00K derived: sum of 2 quarters · filed 2022-11-09 | $933.00K 10-Q · filed 2022-11-09 | $6.75M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $860.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $873.00K 10-Q · filed 2022-08-09 | $6.69M derived: sum of 3 quarters · filed 2023-02-22 | |
| 2021-03-31 | $13.00K 10-Q · filed 2022-05-04 | $5.83M derived: sum of 2 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $16.54M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $10.72M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $192.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |